Pulse Biosciences to Present Data on Nano-Pulse Stimulation Technology for Nodular Basal Cell Carcinoma at IMCAS World Congre...
January 29 2020 - 9:41PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”), a novel
bioelectric medicine company, today announced the presentation of
its scientific study evaluating the clinical and histologic
response of Nano-Pulse Stimulation™ (NPS™) technology in treating
challenging cases of nodular Basal Cell Carcinoma (nBCC). These
results are to be presented at the 22nd annual IMCAS (International
Master Course on Aging Skin) World Congress, the gathering of
international experts in dermatology, plastic surgery and aging
science, taking place at Palais des Congrès, Paris, France, from
January 30th to February 1st 2020.
Dermatologist Girish Munavalli, MD, MHS, FACMS, a prominent skin
cancer surgeon in Charlotte, NC, will present results that
demonstrate the unique ability of NPS technology to eliminate tumor
cells in nodular BCCs while sparing surrounding healthy tissue.
Results will be supported by clinical photos that display a more
favorable cosmetic outcome possible in a short amount of time with
reduced potential for scar formation as compared to current
surgical excision.
Basal cell carcinoma is the most common form of skin cancer
worldwide. The nodular BCC subtype reported in this study comprises
60% of all basal cell carcinomas. For these deep nodular lesions,
the current standard of care is surgical excision, which can lead
to large, permanent scars.
“Early findings show promising potential for NPS technology as a
new treatment option for nodular BCC. NPS technology has
demonstrated equivalent therapeutic benefit and the added benefit
of superior cosmetic outcomes compared to more destructive skin
cancer treatment modalities, such as excision and curettage,” said
Dr. Munavalli of Dermatology, Laser & Vein Specialists of the
Carolinas, Charlotte, NC.
“We are enthusiastic about the impressive results Nano-Pulse
Stimulation technology is producing in Basal Cell Carcinomas and
are focused on rapidly advancing its development program across
multiple clinical applications,” said Darrin Uecker, President and
CEO of Pulse Biosciences. “Our presence at IMCAS represents the
initial step in our commitment to international commercialization,
which aims to extend our long-term growth platform and leverage the
value proposition of our technology’s ability to clear benign and
malignant lesions. “
Scheduled scientific presentation at IMCAS
World Congress 2020
Podium Presentation: “Histologic and Clinical
Comparison of Scar Cosmesis Using Nano-Pulse Stimulation vs
Traditional Surgical Treatments of Basal Cell Carcinoma,” by
Dr. Girish S. MUNAVALLI, Assistant Professor at the Wake
Forest University School of Medicine – Department of Dermatology
and Medical Director and Founder of Dermatology, Laser & Vein
Specialists of the Carolinas, Charlotte NC.
Details: 30 January 2020, at 12:06pm in Room 143, Level 1
Skin Cancer and Photorejuvenation: The Impossible Equation: Session
S011, S012 Chaired by: Dr. Mathew Avram and Pr. Merete
Haedersdal.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that improves and potentially
extends the lives of patients. The CellFX System is the first
planned commercial product to harness the distinctive advantages of
the Company’s proprietary Nano-Pulse Stimulation (NPS) technology
to treat a variety of applications for which an optimal solution
remains unfulfilled. NPS technology delivers nano-second pulses of
electrical energy to non-thermally clear cells while sparing
adjacent non-cellular tissue. The cell-specific effects of NPS
technology have been validated in a series of ongoing clinical
trials. The CellFX System is a multi-application platform designed
to address a broad range of dermatologic conditions. As part of the
customer experience, the Company is offering a utilization-based
revenue model and easy-access customer portal offering a suite of
services. CellFX procedures offer customer value across an
expanding spectrum of clinical applications. The initial commercial
use will be in the clearance of common and difficult-to-treat skin
lesions that share high demand among patients and practitioners for
improved and durable aesthetic outcomes that lead to greater
overall satisfaction.
Caution: Pulse Biosciences’ CellFX
System and Nano-Pulse Stimulation technology are for
investigational use only.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the Company’s CellFX System,
including the progress and timing of the FDA’s review of the
Company’s 510(k) submission, the commercialization of the Company’s
Cell FX System, and the results of clinical study plans. These
forward-looking statements are based on current expectations and
estimates and involve a number of risks and uncertainties that
could cause actual results to differ materially from those
suggested or implied by the forward-looking statements. These
forward-looking statements should, therefore, be considered in
light of various important factors, including, but not limited to,
the following: the impact of governmental regulatory agencies,
including the FDA, and regulatory approvals, clearances and
restrictions or any dispute that may occur with any regulatory
body; risks inherent to the planning, design and execution of
clinical studies; the timing and success of product development;
and other risk factors under the heading “Risk Factors” in the
Company’s most recently filed quarterly report on Form 10-Q and as
periodically updated by the Company’s subsequent filings with the
Securities and Exchange Commission. Statements using words such as
“estimates,” “projects,” “believes,” “anticipates,” “plans,”
“expects,” “intends,” “may,” “will,” “could,” “should,” “would,”
“targeted” and similar words and expressions are intended to
identify forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Pulse Biosciences, Inc.
undertakes no obligation to publicly update or release any
revisions to these forward-looking statements, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200129005866/en/
Investors: Pulse Biosciences Sandra Gardiner, EVP and CFO
510.241.1077 sgardiner@pulsebiosciences.com Media: Tosk
Communications Nadine D. Tosk 504.453.8344 nadinepr@gmail.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Sep 2023 to Sep 2024